BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 June 2008

Br J Ophthalmol. Published Online First: 17 April 2008. doi:10.1136/bjo.2007.126227
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
bjo.2007.126227v1
92/6/810    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Tammewar, A. M
Right arrow Articles by Freeman, W. R
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tammewar, A. M
Right arrow Articles by Freeman, W. R

Original article - Clinical Science

Comparison of 4mg versus 20mg Intravitreal Triamcinolone Acetonide Injections

Ajay M Tammewar 1, Lingyun Cheng 2*, Ozcan R Kayikcioglu 2, Iryna A Falkenstein 2, Igor Kozak 2, Michael H Goldbaum 2 and William R Freeman 2

1 Jacobs Retina Center at UCSD Shiley Eye Center, United States
2 Jacobs Retina Center at Shiley Eye Center, UCSD, United States

* To whom correspondence should be addressed. E-mail: cheng{at}eyecenter.ucsd.edu.

Accepted 5 March 2008


*  Abstract

Aims: To compare the non-decanted (standard) 4mg versus the decanted 20 mg intravitreal triamcinolone acetonide (IVTA) injections and to assess their effect on intraocular pressure (IOP).

Methods: We retrospectively reviewed the records of 92 consecutive eyes, which received an intravitreal injection of either dose of TA, at a single retina center. The change in IOP (elevation of at least 5 mmHg from baseline or above 21 mmHg) was analyzed with a multivariate logistic analysis. The mean follow up period in both groups was 27 weeks. Subgroup analysis comparing vitrectomized to non-vitrectomized eyes in both groups was also performed.

Results: Of the 92 eyes, 46% (23 of 51) in the 4 mg group versus 30 % (12 of 41) in the 20 mg group had an IOP > 21 mm of Hg (p=0.14) after mean follow-up period of 27 weeks. The vitrectomized eyes (3 of 24) in the 20 mg group had a significantly lower rate of IVTA induced IOP elevation than the non-vitrectomized eyes (9 of 17) (p=0.013). The IOP elevation occurred significantly earlier in the 4mg group (vitrectomized eyes 27±43 days and non-vitrectomized eyes 61±52 days) than in the 20 mg group (vitrectomized eyes 104±56 days and non-vitrectomized eyes 119±82 days), independent of the vitreous status (vitrectomized p= 0.05 and non-vitrectomized p=0.04). The mean value of initial high IOP in the non-vitrectomized eyes was higher in 4 mg group than the corresponding 20 mg group (p=0.048).

Conclusion: Decanted 20 mg IVTA may not pose a significantly greater risk of IOP elevation than the 4 mg non-decanted IVTA.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.